Известные лабораторные нарушения и потенциальные молекулы-мишени для консервативного лечения аваскулярного остеонекроза

Аваскулярный остеонекроз (АОН) – распространенная патология, которая наиболее часто поражает людей трудоспособного возраста (20–60 лет). Заболевание приводит к быстрому разрушению и коллапсу субхондральной кости с последующим развитием вторичного остеоартрита пораженного сустава.

Представлен обзор современных данных о лабораторных нарушениях при АОН. Подробно описаны биомаркеры, имеющие прямую связь с развитием и прогрессированием АОН. Сформулированы идеи для будущих исследований, которые помогут улучшить выявление и лечения заболевания.

1. Bergman J, Nordstrцm A, Nordstrцm P. Epidemiology of osteonecrosis among older adults in Sweden. Osteoporos Int. 2019 May; 30(5):965-973. doi: 10.1007/s00198-018-04826-2. Epub 2019 Jan 9.

2. Мустафин РН. Аваскулярный некроз головки бедренной кости в Республике Башкортостан (клинико-эпидемиологическое исследование). Креативная хирургия и онкология. 2020;10(2):100-107.

3. Chang C, Greenspan A, Gershwin ME. The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis. J Autoimmun. 2020 Jun:110:102460. doi: 10.1016/j.jaut.2020.102460. Epub 2020 Apr 16.

4. Тихилов РМ, Шубняков ИИ, редакторы. Руководство по хирургии тазобедренного сустава. Том 1. Санкт-Петербург: РНИИТО им. Р. Р. Вредена; 2014. 368 с.

5. Lespasio MJ, Sodhi N, Mont MA. Osteonecrosis of the Hip: A Primer. Perm J. 2019:23:18-100. doi: 10.7812/TPP/18-100.

6. Glueck CJ, Freiberg R, Tracy T, et al. Thrombophilia and hypofibrinolysis: Pathophysiologies of osteonecrosis. Clin Orthop Relat Res. 1997 Jan:(334):43-56.

7. Kubo T, Tsuji H, Yamamoto T, et al. Antithrombin III deficiency in a patient with multifocal osteonecrosis. Clin Orthop Relat Res. 2000 Sep:(378):306-11. doi: 10.1097/00003086-200009000-00041.

8. Pierre-Jacques H, Glueck CJ, Mont MA, Hungerford DS. Familial heterozygous protein-S deficiency in a patient who had multifocal osteonecrosis. A case report. J Bone Joint Surg Am. 1997 Jul;79(7):1079-84. doi: 10.2106/00004623-199707000-00017.

9. Glueck CJ, Freiberg RA, Fontaine RN, et al. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res. 2001 May:(386):19-33. doi: 10.1097/00003086- 200105000-00004.

10. Zalavras CG, Vartholomatos G, Dokou E, Malizos KN. Factor V Leiden and prothrombin gene mutations in femoral head osteonecrosis. Thromb Haemost. 2002 Jun;87(6): 1079-80.

11. Garcia FL, Ramalli Junior EL, Picado CHF. Coagulation disorders in patients with femoral head osteonecrosis. Acta Ortop Bras. 2013 Jan;21(1):43-5. doi: 10.1590/S1413-78522013000100009.

12. Arruda VR, Belangero WD, Ozelo MC, et al. Inherited risk factors for thrombophilia among children with Legg-Calve-Perthes disease. J Pediatr Orthop. 1999 Jan-Feb;19(1):84-7.

13. Bjorkman A, Burtscher IM, Svensson PJ, et al. Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee. Arch Orthop Trauma Surg. 2005 Feb;125(1):51-5. doi: 10.1007/s00402-004-0760-8. Epub 2004 Nov 18.

14. Baek SH, Kim KH, Lee WK, et al. Abnormal Lipid Profiles in Nontraumatic Osteonecrosis of the Femoral Head: A Comparison with Osteoarthritis Using Propensity Score Matching. J Bone Joint Surg Am. 2022 Apr 6;104(Suppl 2):19-24. doi: 10.2106/JBJS.20.00520.

15. Glueck C, Fontaine R, Gruppo R, et al. The Plasminogen Activator Inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop Relat Res. 1999 Sep:(366):133-46. doi: 10.1097/00003086-199909000-00017.

16. Glueck C, Freiberg R, Wang P. Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head. Clin Orthop Relat Res. 2008 May;466(5):1034-40. doi: 10.1007/s11999-008-0148-0. Epub 2008 Mar 19.

17. Chotanaphuti T, Heebthamai D, Chuwong M, Kanchanaroek K. The prevalence of thrombophilia in idiopathic osteonecrosis of the hip. J Med Assoc Thai. 2009 Dec;92 Suppl 6:S141-6.

18. Glueck CJ, Glueck HI, Mieczkowski L, et al. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis? Thromb Haemost. 1993 May 3;69(5):460-5.

19. Asherson RA, Liote F, Page B, et al. Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol. 1993 Feb;20(2):284-8.

20. Korompilias AV, Gilkeson GS, Ortel TL, et al. Anticardiolipin antibodies and osteonecrosis of the femoral head. Clin Orthop Relat Res. 1997 Dec:(345):174-80.

21. Hirata T, Fujioka M, Takahashi KA, et al. Low molecular weight phenotype of Apo(a) is a risk factor of corticosteroid-induced osteonecrosis of the femoral head after renal transplant. J Rheumatol. 2007 Mar;34(3):516-22.

22. Hussein S, Suitner M, Beland-Bonenfant S, et al. Monitoring of osteonecrosis in systemic lupus erythematosus: A systematic review and metaanalysis. J Rheumatol. 2018 Oct;45(10): 1462-1476. doi: 10.3899/jrheum.170837. Epub 2018 Jul 1.

23. Haydock MM, Elhamdani S, Alsharedi M. Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor. SAGE Open Med Case Rep. 2019 Feb 4:7:2050313X19827747. doi: 10.1177/2050313X19827747. eCollection 2019.

24. Jarman MI, Lee K, Kanevsky A, et al. Case report: primary osteonecrosis associated with thrombophilia-hypofibrinolysis and worsened by testosterone therapy. BMC Hematol. 2017 Mar 27:17:5. doi: 10.1186/s12878-017-0076-x. eCollection 2017.

25. Fu W, Liu B, Wang B, Zhao D. Early diagnosis and treatment of steroid-induced osteonecrosis of the femoral head. Int Orthop. 2019 May;43(5):1083-1087. doi: 10.1007/s00264-018-4011-y. Epub 2018 Jun 6.

26. Glueck CJ, Freiberg RA, Wissman R, Wang P. Long term anticoagulation (4-16 years) stops progression of idiopathic hip osteonecrosis associated with familial thrombophilia. Adv Orthop. 2015:2015:138382. doi: 10.1155/2015/138382. Epub 2015 Jan 29.

27. Guo P, Gao F, Wang Y, et al. The use of anticoagulants for prevention and treatment of osteonecrosis of the femoral head: A systematic review. Medicine (Baltimore). 2017 Apr; 96(16):e6646. doi: 10.1097/MD.0000000000006646.

28. Yu X, Zhang S, Zhang B, Dai M. Relationship of idiopathic femoral head necrosis with blood lipid metabolism and coagulation function: A propensity score-based analysis. Front Surg. 2023 Jan 6:9:938565. doi: 10.3389/fsurg.2022.938565. eCollection 2022.

29. Zeng X, Zhan K, Zhang L, et al. The impact of high total cholesterol and high lowdensity lipoprotein on avascular necrosis of the femoral head in low-energy femoral neck fractures. J Orthop Surg Res. 2017 Feb 17; 12(1):30. doi: 10.1186/s13018-017-0532-0.

30. Mogensen SS, Schmiegelow K, Grell K, et al. Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia. Haematologica. 2017 May;102(5):e175-e178. doi: 10.3324/haematol.2016.160507. Epub 2017 Feb 16.

31. Nishida K, Yamamoto T, Motomura G, et al. Pitavastatin may reduce risk of steroidinduced osteonecrosis in rabbits: a preliminary histological study. Clin Orthop Relat Res. 2008 May;466(5):1054-8. doi: 10.1007/s11999-008-0189-4. Epub 2008 Mar 19.

32. Yang Z, Liu H, Li D, et al. The efficacy of statins in preventing glucocorticoid-related osteonecrosis in animal models: A metaanalysis. Bone Joint Res. 2016 Sep;5(9):393- 402. doi: 10.1302/2046-3758.59.2000500.

33. Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res. 2001 May: (386):173-8. doi: 10.1097/00003086-200105000-00022.

34. Mont MA, Pivec R, Banerjee S, et al. High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review. J Arthroplasty. 2015 Sep;30(9):1506-1512.e5. doi: 10.1016/j.arth.2015.03.036. Epub 2015 Apr 8.

35. Yin H, Yuan Z, Wang D. Multiple drilling combined with simvastatin versus multiple drilling alone for the treatment of avascular osteonecrosis of the femoral head: 3-year follow-up study. BMC Musculoskelet Disord. 2016 Aug 15;17(1):344. doi: 10.1186/s12891-016-1199-0.

36. Ajmal M, Matas AJ, Kuskowski M, Cheng EY. Does statin usage reduce the risk of corticosteroid-related osteonecrosis in renal transplant population? Orthop Clin North Am. 2009 Apr;40(2):235-9. doi: 10.1016/j.ocl.2009.01.004.

37. Funck-Brentano T, Biver E, Chopin F, et al. Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: a systematic review. Semin Arthritis Rheum. 2011 Oct;41(2):157-69. doi: 10.1016/j.semarthrit.2011.01.005. Epub 2011 Apr 19.

38. Bhattoa HP, Cavalier E, Eastell R, et al. Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood. Clin Chim Acta. 2021 Apr:515:16-20. doi: 10.1016/j.cca.2020.12.023. Epub 2020 Dec 28.

39. Cavalier E, Eastell R, Jørgensen NR, et al. A Multicenter Study to Evaluate Harmonization of Assays for C-Terminal Telopeptides of Type I Collagen (β-CTX): A Report from the IFCC-IOF Committee for Bone Metabolism (C-BM). Calcif Tissue Int. 2021 Jun;108(6): 785-797. doi: 10.1007/s00223-021-00816-5. Epub 2021 Mar 4.

40. Chubb SAP, Vasikaran SD. Measurement and Clinical Utility of β-CTX in Serum and Plasma. Adv Clin Chem. 2017:81:97-134. doi: 10.1016/bs.acc.2017.01.003. Epub 2017 Feb 16.

41. Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol. 2014 Oct 20:5:511. doi: 10.3389/fimmu.2014.00511. eCollection 2014.

42. Аганов ДС, Тыренко ВВ, Цыган ЕН и др. Роль цитокиновой системы RANKL/RANK/OPG в регуляции минерального обмена костной ткани. Гены & Клетки. 2014; XI(4):50-52.

43. Xiong MY, Liu LQ, Liu SQ, et al. Effects of osteoprotegerin, RANK and RANKL on bone destruction and collapse in avascular necrosis femoral head. Am J Transl Res. 2016 Jul 15;8(7):3133-40. eCollection 2016.

44. Kovacs B, Vajda E, Nagy EE. Regulatory Effects and Interactions of the Wnt and OPGRANKL-RANK Signaling at the Bone-Cartilage Interface in Osteoarthritis. Int J Mol Sci. 2019 Sep 19;20(18):4653. doi: 10.3390/ijms20184653.

45. He MC, Zhang J, Chen XJ, et al. Osteoclastic activity was associated with the development of steroid-induced osteonecrosis of femoral head. Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):1036-1046. doi: 10.1080/21691401.2020.1774596.

46. Yue YB, Liu X, Wei BF. Attenuated serum adiponectin levels are associated with disease severity in patients with non-traumatic osteonecrosis of the femoral head. J Pain Res. 2017 Oct 3:10:2387-2393. doi: 10.2147/JPR. S143036. eCollection 2017.

47. Peng X, Ma Y, Wang Q, et al. Serum Amyloid A Correlates With the Osteonecrosis of Femoral Head by Affecting Bone Metabolism. Front Pharmacol. 2021 Oct 18:12:767243. doi: 10.3389/fphar.2021.767243. eCollection 2021.

48. Ghale-Noie ZN, Hassani M, Kachooei AR, Kerachian MA. High Serum Alpha-2-Macroglobulin Level in Patients with Osteonecrosis of the Femoral Head. Arch Bone Jt Surg. 2018 May;6(3):219-224.

49. Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004 Oct;35(4):842-9. doi: 10.1016/j.bone.2004.06.008.

50. Lenchik L, Register TC, Hsu FC, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone. 2003 Oct;33(4):646-51. doi: 10.1016/s8756-3282(03)00237-0.

51. Shuai B, Shen L, Yang YP, et al. Low plasma adiponectin as a potential biomarker for osteonecrosis of the femoral head. J Rheumatol. 2010 Oct;37(10):2151-5. doi: 10.3899/jrheum.100342. Epub 2010 Aug 3.

52. Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics of the Gut Microbial Ecosystem in Inflammatory Bowel Diseases. Nature. 2019 May;569(7758):655-662. doi: 10.1038/s41586-019-1237-9. Epub 2019 May 29.

53. Husebekk A, Skogen B, Husby G, Marhaug G. Transformation of Amyloid Precursor SAA to Protein AA and Incorporation in Amyloid Fibrils In Vivo. Scand J Immunol. 1985 Mar;21(3):283-7. doi: 10.1111/j.1365-3083.1985.tb01431.x.

54. Sack GH Jr. Serum amyloid A – a review. Mol Med. 2018 Aug 30;24(1):46. doi: 10.1186/s10020-018-0047-0.

55. Vandooren J, Itoh Y. Alpha-2-Macroglobulin in Inflammation, Immunity and Infections. Front Immunol. 2021 Dec 14:12:803244. doi: 10.3389/fimmu.2021.803244. eCollection 2021.

56. Ekerot L, Ohlsson K. Immunoreactive Alpha 2-Macroglobulin in Rheumatoid Synovial Membrane. Scand J Plast Reconstr Surg. 1982;16(3):293-4. doi: 10.3109/02844318209026222.

57. Flory ED, Clarris BJ, Muirden KD. Deposits of Alpha 2M in the Rheumatoid Synovial Membrane. Ann Rheum Dis. 1982 Oct;41(5):520-6. doi: 10.1136/ard.41.5.520.